Abstract
Hereditary breast and ovarian cancer (HBOC) syndrome and a rare childhood disorder Fanconi anemia (FA) are caused by homologous recombination (HR) defects, and some of the causative genes overlap. Recent studies in this field have led to the exciting development of PARP inhibitors as novel cancer therapeutics and have clarified important mechanisms underlying genome instability and tumor suppression in HR-defective disorders. In this review, we provide an overview of the basic molecular mechanisms governing HR and DNA crosslink repair, highlighting BRCA2, and the intriguing relationship between HBOC and FA.
Original language | English |
---|---|
Pages (from-to) | T19-T37 |
Journal | Endocrine-Related Cancer |
Volume | 23 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 2016 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Oncology
- Endocrinology
- Cancer Research